stockrow
Monday 9 November 2026
Export ORMP’s income statement to Excel — free account
Oramed Pharmaceuticals Inc.
ORMPOramed Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 49.3% from fiscal 2023.
- Revenue
- +193.3%
- EPS
- +493.8%
- Free cash flow
- +94.3%
Quarter to June 2026, against a year earlier
3.86
0.03
−0.77%
Follow ORMP
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Aug '22 | Dec '21 | Aug '21 | Aug '20 | Aug '19 | Aug '18 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 4 | 5 | 3 | 3 |
P/E ratio |
1.88 | — | 17.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
29.35 | — | 36.54 | 178.90 | 123.22 | 194.84 | 238.42 | 26.44 | 20.79 | 30.08 |
Altman Z-Score |
1.91 | — | 0.33 | 25.74 | 17.17 | 28.10 | 28.25 | 0.91 | (1.34) | 0.45 |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | 0.00 | 107.97 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
7.80 | — | 3.41 | 16.30 | 14.68 | 18.01 | 11.00 | (0.31) | (3.83) | (1.01) |
P/Operating CF |
(253.22) | — | (69.66) | (59.98) | (39.11) | 190.84 | (102.70) | (5.76) | (4.34) | (5.03) |
P/B ratio |
0.59 | — | 0.61 | 3.20 | 2.17 | 3.18 | 5.53 | 2.18 | 2.90 | 2.37 |
Dividend Safety Score |
45 | — | — | — | — | — | — | — | — | — |
Price to Tangible BV |
0.59 | — | 0.61 | 3.20 | 2.17 | 3.18 | 5.53 | 2.18 | 2.90 | 2.37 |
EV/Sales |
(1.96) | — | (23.41) | 121.29 | 73.53 | 141.06 | 203.61 | 11.72 | 8.85 | 17.64 |
EV/EBITDA |
0.53 | — | 4.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.86 | — | 6.15 | (11.74) | (25.27) | 82.77 | (37.85) | (1.25) | (0.89) | (1.58) |
EV/FCF |
0.86 | — | 6.00 | (11.55) | (26.18) | 78.17 | (37.60) | (1.25) | (0.89) | (1.58) |
Quick Ratio |
6.60 | 24.97 | 3.05 | 27.10 | 27.10 | 19.85 | 14.09 | 8.80 | 6.08 | 6.69 |
Current Ratio |
6.98 | 25.19 | 3.06 | 27.34 | 27.34 | 20.08 | 14.27 | 8.93 | 6.28 | 6.82 |
Net Debt/EBITDA |
8.41 | 11.28 | 10.41 | 3.84 | 3.84 | 11.89 | 3.90 | 3.40 | 2.21 | 2.25 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 | 0.03 | 0.07 | 0.07 | 0.06 |
Operating CF/Net income |
(0.14) | 0.44 | (1.86) | 0.76 | 0.79 | 0.95 | 0.95 | 1.08 | 0.90 | 1.15 |
Capex/Depreciation |
(0.07) | (0.09) | (1.30) | (8.14) | 0.00 | (0.50) | (4.87) | (11.71) | (1.87) | (0.83) |
Interest Coverage |
— | (14.98) | (7.74) | (49.51) | (22.72) | (141.68) | (3,027.87) | (26.48) | (30.17) | (131.33) |
| 36.65% | (12.37%) | 3.52% | (24.14%) | (22.96%) | (8.24%) | (29.77%) | (44.04%) | (56.85%) | (50.55%) | |
| 32.76% | (10.14%) | 2.89% | (22.62%) | (21.54%) | (7.63%) | (25.76%) | (29.03%) | (34.99%) | (29.56%) | |
ROIC |
(12.77%) | (233.78%) | (1,164.97%) | 0.00% | 0.00% | (37.89%) | (67.66%) | 0.00% | 0.00% | (1,302.68%) |
Return on Tangible Assets |
55.10% | (13.79%) | 5.01% | (24.03%) | (23.87%) | (8.28%) | (24.97%) | (31.91%) | (51.19%) | (48.02%) |
Average Days of Receivables |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
319.05% | 0.00% | 669.48% | 1,022.53% | 1,020.38% | 999.67% | 776.51% | 377.68% | 500.26% | 489.14% |
Selling, General and Administrative Expense of Revenue |
436.00% | 0.00% | 607.31% | 579.43% | 579.43% | 463.83% | 219.64% | 156.16% | 137.70% | 166.72% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
299.60% | 0.00% | 314.33% | 425.79% | 0.00% | 196.46% | 99.70% | 17.16% | 29.89% | 63.17% |
Graham Net Nets |
0.87 | — | 1.06 | 0.30 | 0.38 | 0.26 | 0.13 | 0.40 | 0.32 | 0.20 |
Graham Number |
12.85 | — | 3.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
53.33% | — | 5.71% | (7.58%) | (11.46%) | (6.03%) | (3.53%) | (16.36%) | (17.45%) | (17.37%) |
Free Cash Flow Yield |
(7.76%) | — | (10.68%) | (5.87%) | (2.28%) | 0.93% | (2.27%) | (35.59%) | (47.65%) | (37.21%) |
Revenue per Share |
0.05 | 0.00 | 0.03 | 0.07 | 0.07 | 0.02 | 0.09 | 0.13 | 0.15 | 0.16 |
Operating CF per Share |
(0.22) | (0.21) | (0.26) | (0.72) | (0.74) | (0.30) | (0.74) | (0.61) | (0.74) | (0.98) |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.22) | (0.21) | (0.26) | (0.73) | (0.74) | (0.30) | (0.76) | (0.61) | (0.74) | (0.99) |
Cash per Share |
3.04 | 3.47 | 4.02 | 3.99 | 3.99 | 3.94 | 3.31 | 1.94 | 1.85 | 2.05 |
Shareholders Equity per Share |
4.82 | 3.56 | 4.04 | 3.88 | 3.89 | 4.49 | 4.09 | 1.60 | 1.11 | 2.09 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.82 | 3.56 | 4.04 | 3.88 | 3.89 | 4.49 | 4.09 | 1.60 | 1.11 | 2.09 |
Free Cash Flow |
(9.15) | (8.43) | (10.55) | (28.39) | (28.70) | (11.13) | (21.56) | (12.52) | (12.95) | (14.66) |
Working Capital |
114.19 | 137.54 | 109.37 | 151.36 | 151.36 | 140.57 | 88.66 | 35.98 | 28.02 | 26.48 |
Capital Expenditures |
(0.01) | (0.02) | (0.25) | (0.47) | (0.50) | (0.01) | (0.37) | (0.08) | (0.01) | 0.00 |
Net Current Asset Value |
102.15 | 133.29 | 104.93 | 146.62 | 146.62 | 136.73 | 83.86 | 28.76 | 18.05 | 14.75 |
EV/EBIT |
0.52 | — | 4.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.19 | 0.17 | 0.00 | 0.01 | 0.14 | 0.03 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.21 | 0.28 | 0.22 | 0.07 | 0.03 | 0.05 | 0.19 | 0.07 | 0.33 | 0.35 |
Cash ROIC |
(2.81%) | (2.93%) | (3.25%) | (9.25%) | (9.33%) | (3.56%) | (10.23%) | (17.21%) | (25.07%) | (23.81%) |
Accounts Receivable Turnover |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | (0.04) |
Inventory Turnover |
0.00 | — | — | — | — | — | — | — | 0.00 | 0.00 |
Average Days of Payables |
1,258.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10,564.72 | (8,929.77) |
Days of Inventory on Hand |
0.00 | — | — | — | — | — | — | — | 0.00 | 0.00 |
Average Payables |
6.16 | 3.70 | 3.05 | 3.17 | 3.36 | 4.19 | 2.82 | 2.20 | 2.35 | 2.41 |
Average Assets |
193.07 | 187.91 | 191.10 | 161.64 | 169.73 | 152.91 | 86.32 | 39.65 | 41.03 | 43.05 |
Average Common Equity |
172.55 | 154.12 | 157.02 | 151.48 | 159.21 | 141.56 | 74.70 | 26.14 | 25.25 | 25.18 |
Columns are period end dates · fundamentals updated 2 Nov 2026